{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:25:59Z","timestamp":1789961159120,"version":"4.0.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T00:00:00Z","timestamp":1601078400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To investigate safety and efficacy of MMF in patients with severe or MTX-refractory juvenile localized scleroderma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Consecutive juvenile localized scleroderma patients undergoing systemic treatment were included in a retrospective longitudinal study. Patients treated with MMF because they were refractory or intolerant to MTX (MMF-group) were compared with responders to MTX (MTX-group). Disease activity was assessed by Localized Scleroderma Cutaneous Assessment Tool and thermography. Disease course was established on the number of relapses and treatment changes. Relapse-free survival was examined by Kaplan\u2013Meier analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>MMF and MTX groups included 22 and 47 patients, respectively. No significant difference in demographics, follow-up duration and treatment before diagnosis was observed between groups. The most represented clinical subtypes in the MMF-group were pansclerotic morphea and mixed subtype (P\u2009=\u20090.008 and P\u2009=\u20090.029, respectively), and linear scleroderma of the face in the MTX-group (P\u2009=\u20090.048). MMF was started because of MTX resistance (18 patients), relapse during MTX tapering\/withdrawal (3 patients) and anaphylaxis to MTX (1 patient). After mean 9.4\u2009years of follow-up, 90.9% of patients on MMF and 100% of those on MTX had inactive disease. No significant difference in relapse-free survival between the groups was found (P\u2009=\u20090.066, log-rank test), although MMF likely induced more persistent remission. MMF was well tolerated and combination of MMF and MTX did not increase its efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present study adds strong evidence on the efficacy and tolerance of MMF in severe and\/or MTX-refractory juvenile localized scleroderma. Further controlled studies are needed to prove its efficacy as first line treatment.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa392","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T19:12:01Z","timestamp":1592334721000},"page":"1387-1391","source":"Crossref","is-referenced-by-count":27,"title":["Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3801-8903","authenticated-orcid":false,"given":"Giorgia","family":"Martini","sequence":"first","affiliation":[{"name":"Paediatric Rheumatology Unit, Department of Woman and Child Health, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Saggioro","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Unit, Department of Woman and Child Health, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Culpo","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Unit, Department of Woman and Child Health, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Vittadello","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Unit, Department of Woman and Child Health, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Meneghel","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Unit, Department of Woman and Child Health, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-3485","authenticated-orcid":false,"given":"Francesco","family":"Zulian","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology Unit, Department of Woman and Child Health, University of Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,25]]},"reference":[{"key":"2021030705490113100_keaa392-B1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.pcl.2018.04.002","article-title":"Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis","volume":"65","author":"Li","year":"2018","journal-title":"Pediatr Clin North Am"},{"key":"2021030705490113100_keaa392-B2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archdermatol.2010.239","article-title":"An evaluation of long-term outcomes in adults with pediatric-onset morphea","volume":"146","author":"Saxton-Daniels","year":"2010","journal-title":"Arch Dermatol"},{"key":"2021030705490113100_keaa392-B3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.autrev.2018.02.004","article-title":"Disease course and long-term outcome of juvenile localized scleroderma: experience from a single pediatric rheumatology centre and literature review","volume":"17","author":"Martini","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2021030705490113100_keaa392-B4","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.30264","article-title":"Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Zulian","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2021030705490113100_keaa392-B5","first-page":"286","article-title":"Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single center study","volume":"39","author":"Torok","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2021030705490113100_keaa392-B6","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.semarthrit.2016.08.018","article-title":"Early- and late-stage morphea subtypes with deep tissue involvement is treatable with abatacept","volume":"46","author":"Adeeb","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2021030705490113100_keaa392-B7","first-page":"211","article-title":"Tocilizumab in two children with pansclerotic morphea: a hopeful therapy for refractory cases?","volume":"35(Suppl 106","author":"Martini","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2021030705490113100_keaa392-B8","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/rheumatology\/kex382","article-title":"Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma","volume":"57","author":"Lythgoe","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2021030705490113100_keaa392-B9","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/rheumatology\/kep244","article-title":"Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil","volume":"48","author":"Martini","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2021030705490113100_keaa392-B10","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2340\/00015555-2297","article-title":"Use of mycophenolate mofetil in patients with severe localized sclerodema resistant or intolerant to methotrexate","volume":"96","author":"Mertens","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"2021030705490113100_keaa392-B11","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/01.bor.0000245727.40630.c3","article-title":"Localized scleroderma","volume":"18","author":"Laxer","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"2021030705490113100_keaa392-B12","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/rheumatology\/41.10.1178","article-title":"Juvenile-onset localized scleroderma activity detection by infrared thermography","volume":"41","author":"Martini","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"2021030705490113100_keaa392-B13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/rheumatology\/kep361","article-title":"Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study","volume":"49","author":"Arkachaisri","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2021030705490113100_keaa392-B14","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.semarthrit.2015.06.006","article-title":"Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles","volume":"45","author":"Torok","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2021030705490113100_keaa392-B15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jaut.2019.04.008","article-title":"The identification of CCL18 as biomarker of disease activity in localized scleroderma","volume":"101","author":"Mertens","year":"2019","journal-title":"J Autoimmun"},{"key":"2021030705490113100_keaa392-B16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021030705490113100_keaa392-B17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.106.117051","article-title":"In vitro evidence for a direct anti-fibrotic role of the immunosuppressive drug mycophenolate mofetil","volume":"321","author":"Roos","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"2021030705490113100_keaa392-B18","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jid.2018.01.006","article-title":"Mycophenolate mofetil treatment of systemic sclerosis reduces myeloid cell numbers and attenuates the inflammatory gene signature in skin","volume":"138","author":"Hinchcliff","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2021030705490113100_keaa392-B19","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/ard.2010.142000","article-title":"Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis","volume":"70","author":"Le","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021030705490113100_keaa392-B20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/3\/1387\/36434294\/keaa392.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/3\/1387\/36434294\/keaa392.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T22:14:50Z","timestamp":1666995290000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/3\/1387\/5911878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,25]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9,25]]},"published-print":{"date-parts":[[2021,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa392","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,9,25]]}}}